<DOC>
	<DOCNO>NCT01930175</DOCNO>
	<brief_summary>To evaluate safety , tolerability efficacy single intravneous infusion VAY736 , compare placebo , pemphigus vulgaris patient .</brief_summary>
	<brief_title>Study Efficacy Safety VAY736 Patients With Pemphigus Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<criteria>Adult patient 20 70 year age Confirmed diagnosis pemphigus vulgaris Presence mild moderate pemphigus vulgaris Patients must weight 40 kg 150 kg inclusive stable dose oral corticosteriod therapy ( without azathioprine mycophenolate ) Pregnant nursing ( lactate ) woman Women childbearing potential unless use highly effective method birth control dose 4 month follow study treatment Recent previous treatment photo therapy , biological therapy , steroid , immunosuppresive agent ( unless washout period apply ) Active recent history clinically significant infection use rituximab within 1 year Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pemphigus vulgaris</keyword>
	<keyword>pemphigus</keyword>
	<keyword>blister disease</keyword>
</DOC>